Quick Answer
MoonLake Immunotherapeutics reported Operating Income of -$244.83 million for fiscal year 2025.
MoonLake Immunotherapeutics Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$244.83M | -71.1% |
| 2024 | -$143.09M | -164.4% |
| 2023 | -$54.12M | +16.8% |
| 2022 | -$65.06M | -1323.6% |
| 2021 | -$4.57M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$71.43M | -65.7% | -17.7% |
| June 30, 2025 | -$60.70M | -98.5% | -27.8% |
| March 31, 2025 | -$47.48M | -139.6% | -10.1% |
| September 30, 2024 | -$43.11M | -232.2% | -41.0% |
| June 30, 2024 | -$30.58M | -131.9% | -54.3% |
| March 31, 2024 | -$19.82M | -53.3% | -52.7% |
| September 30, 2023 | -$12.98M | +12.1% | +1.6% |
| June 30, 2023 | -$13.19M | +25.3% | -2.0% |
- MoonLake Immunotherapeutics showed a decrease of -71.1% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, MoonLake Immunotherapeutics’s operating income has declined by 5257.0% (from -$4.57 million to -$244.83 million).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: